Bosutinib and exemestane (EXE) versus EXE alone in postmenopausal (postm) women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (ABC).

被引：1
|
作者：
Moy, B.
Lebrun, F.
Bellet, M.
Chow, L.
Lang, I.
Xu, B.
Badwe, R. A.
Hershman, D. L.
Leip, E.
Bardy-Bouxin, N.
Duvillie, L.
Neven, P.
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Inst Jules Bordet, B-1000 Brussels, Belgium
[3] Vall dHebron Univ Hosp, Barcelona, Spain
[4] Unimed Med Inst, Comprehens Ctr Breast Dis, Hong Kong, Hong Kong, Peoples R China
[5] Orszagos Onkol Intezet, Budapest, Hungary
[6] Chinese Acad Med Sci, Canc Hosp, Beijing 100730, Peoples R China
[7] Tata Mem Hosp, Bombay 400012, Maharashtra, India
[8] Columbia Univ, Med Ctr, New York, NY USA
[9] Pfizer Inc, Cambridge, MA USA
[10] Pfizer Global Res & Dev, Paris, France
[11] UZ Leuven, Louvain, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.631
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
631
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?
    Aapro, Matti
    De Laurentiis, Michelino
    Rea, Dan
    Bargallo Rocha, Juan Enrique
    Elizalde, Roberto
    Landherr, Laszlo
    Linderholm, Barbro
    Mamounas, Eleftherios
    Markopoulos, Christos
    Neven, Patrick
    Petrovsky, Alexander
    Rouzier, Roman
    Smit, Vincent
    Svedman, Christer
    Schneider, Daniel
    Thomssen, Christoph
    Martin, Miguel
    BREAST, 2017, 33 : 191 - 199
  • [22] The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2-) advanced/metastatic breast cancer
    Bardia, Aditya
    Mayer, Ingrid
    Winer, Eric
    Linden, Hannah M.
    Ma, Cynthia X.
    Parker, Barbara A.
    Bellet, Meritxell
    Arteaga, Carlos L.
    Cheeti, Sravanthi
    Gates, Mary
    Chang, Ching-Wei
    Fredrickson, Jill
    Spoerke, Jill M.
    Moore, Heather M.
    Giltnane, Jennifer
    Friedman, Lori S.
    Maneval, Edna Chow
    Chan, Iris
    Jhaveri, Komal
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 197 (02) : 319 - 331
  • [23] A phase 1/2 dose escalation and expansion study of OP-1250 in adults with advanced and/or metastatic hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer
    Alemany, Carlos
    Patel, Manish
    Mitri, Zahi
    Sparano, Joseph
    Borges, Virginia
    Makower, Della
    Klein, Pam
    Lawrence, Julia
    Le, Trinh
    Zujewski, Jo Anne
    Harmilton, Erika
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [24] The clinical impact of NOLUS in unresectable/metastatic hormone receptor-positive (HR+)/HER2-negative breast cancer
    Tajiri, Wakako
    Nakamura, Yoshiaki
    Kawasaki, Junji
    Koi, Yumiko
    Akiyoshi, Sayuri
    Koga, Chinami
    Tokunaga, Eriko
    CANCER RESEARCH, 2024, 84 (09)
  • [25] Bosutinib in Combination With the Aromatase Inhibitor Exemestane: A Phase II Trial in Postmenopausal Women With Previously Treated Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer
    Moy, Beverly
    Neven, Patrick
    Lebrun, Fabienne
    Bellet, Meritxell
    Xu, Binghe
    Sarosiek, Tomasz
    Chow, Louis
    Goss, Paul
    Zacharchuk, Charles
    Leip, Eric
    Turnbull, Kathleen
    Bardy-Bouxin, Nathalie
    Duvillie, Ladan
    Lang, Istvan
    ONCOLOGIST, 2014, 19 (04): : 346 - 347
  • [26] Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib plus letrozole in hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC).
    Hortobagyi, Gabriel N.
    Stemmer, Salomon M.
    Burris, Howard A.
    Yap, Yoon Sim
    Sonke, Gabe S.
    Paluch-Shimon, Shani
    Campone, Mario
    Petrakova, Katarina
    Blackwell, Kimberly L.
    Winer, Eric P.
    Janni, Wolfgang
    Verma, Sunil
    Conte, Pier Franco
    Arteaga, Carlos L.
    Cameron, David A.
    Xuan, Fengjuan
    Miller, Michelle Kristine
    Germa, Caroline
    Hirawat, Samit
    O'Shaughnessy, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [27] Sacituzumab govitecan for hormone receptor-positive HER2-negative advanced breast cancer
    Garrigos, Laia
    Camacho, Daniela
    Perez-Garcia, Jose Manuel
    Llombart-Cussac, Antonio
    Cortes, Javier
    Antonarelli, Gabriele
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (10) : 949 - 958
  • [28] Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer
    Lopez-Tarruella, Sara
    Jerez, Yolanda
    Marquez-Rodas, Ivan
    Echavarria, Isabel
    Martin, Miguel
    FUTURE ONCOLOGY, 2017, 13 (24) : 2137 - 2149
  • [29] Immunotherapy for hormone receptor-positive HER2-negative breast cancer
    Cardoso, Fatima
    Hirshfield, Kim M.
    Kraynyak, Kimberly A.
    Tryfonidis, Konstantinos
    Bardia, Aditya
    NPJ BREAST CANCER, 2024, 10 (01)
  • [30] Ipatasertib (ipat) in combination with palbociclib (palbo) and fulvestrant (fulv) in patients (pts) with hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC)
    Oliveira, Mafalda
    Bardia, Aditya
    Kim, Sung-Bae
    Niikura, Naoki
    Hernando, Cristina
    Werutsky, Gustavo
    Antill, Yoland
    Liedke, Pedro
    Oakman, Catherine
    Tokunaga, Eriko
    Wander, Seth
    Krause, Vanessa
    Yamashita, Toshinari
    Schimmoller, Frauke
    Rotmensch, Jacob
    Savage, Heidi
    Sane, Rucha
    Turner, Nicholas
    CANCER RESEARCH, 2022, 82 (04)
12345